Key result
HbA1c variability predicts major cardiovascular events in type 2 diabetes, especially with lower mean HbA1c.
Cohort (n=101,533)
Answers are grounded in this paper and cite their sources.
BACKGROUND: HbA1c variability has emerged as risk factor for cardiovascular diseases in diabetes. However, the impact of HbA1c variability on cardiovascular diseases in subjects within the recommended HbA1c target has been relatively unexplored. METHODS: Using data from a large database, we studied 101,533 people with type 2 diabetes without cardiovascular diseases. HbA1c variability was expressed as quartiles of the standard deviation of HbA1c during three years (exposure phase). The primary composite outcome included non-fatal myocardial infarction, non-fatal stroke, all-cause mortality and was assessed during five years following the first three years of exposure to HbA1c variability (longitudinal phase). An expanded composite outcome including non-fatal myocardial infarction, non-fatal stroke, coronary revascularization/reperfusion procedures, peripheral revascularization procedures, and all-cause mortality was also considered, as well as a series of specific cardiovascular complications. Cox models were adjusted for a large range of risk factors and results were expressed as adjusted hazard ratios. RESULTS: An association between HbA1c variability and all the outcomes considered was found. The correlation between HbA1c variability and cardiovascular complications development was confirmed in both the subgroups of subjects with a mean HbA1c ≤ 53 mmol/mol (recommended HbA1c target) or > 53 mmol/mol during the exposure phase. The risk related to HbA1c variability was higher in people with mean HbA1c ≤ 53 mmol/mol for the primary outcome (p for interaction 0.004), for the expanded secondary outcome (p for interaction 0.001) and for the stroke (p for interaction 0.001), even though HbA1c remained at the target during the follow-up. CONCLUSIONS: These findings suggest that HbA1c variability may provide additional information for an optimized management of diabetes, particularly in people within the target of HbA1c.
No takes yet. Share an insight, caveat, or question.
Ceriello et al. (2022) conducted a cohort in Type 2 diabetes without cardiovascular diseases (n=101,533). HbA1c variability (quartiles of the standard deviation of HbA1c during three years) vs. Lower quartiles of HbA1c variability / comparison across mean HbA1c subgroups (≤53 vs >53 mmol/mol) was evaluated on Composite of non-fatal myocardial infarction, non-fatal stroke, and all-cause mortality (p=0.004 for interaction). HbA1c variability predicted cardiovascular complications in type 2 diabetes, with higher risk for the primary composite outcome when mean HbA1c was ≤53 mmol/mol.
Synapse has enriched 10 related papers. Consider them for comparative context: